disclosures clinical approach: evaluating ctd-ild for the … · 2016. 11. 15. · risk factors ctd...
TRANSCRIPT
-
11/5/2016
1
Clinical Approach: Evaluating CTD-ILD for the pulmonologist
Aryeh Fischer, MDAssociate Professor of Medicine
Division of RheumatologyDivision of Pulmonary Sciences and Critical Care Medicine
University of Colorado School of Medicine
Disclosures
• Industry relationships:
Actelion, aTyr Pharma, Boehringer-Ingelheim, Genentech-Roche, Gilead
ILD in CTD• Occurs commonly across the entire spectrum of CTD
• A multidisciplinary approach can be be useful
• Potentially the most devastating of pulmonary manifestations
• Poses significant challenges to the practicing clinician
“connective tissue disease”or
“collagen vascular disease” • spectrum of systemic
autoimmune diseases characterized by:– circulating autoantibodies– immune-mediated organ
damage– significant clinical
heterogeneity
The CTDs
• Rheumatoid arthritis• Systemic lupus erythematosus• Sjögren’s syndrome• Poly-/Dermatomyositis• Systemic sclerosis
(scleroderma)• Mixed CTD• Undifferentiated CTD
-
11/5/2016
2
ILDCTD
CTD-ILD represents a spectrum of diseases
CTDs
RASLESjSPM/DMSScMCTDUCTD
ILDs
NSIPUIPOPLIPDAD
Estimated prevalence rates of ILD in the various CTDs??
Adapted from Castelino and Varga Arthritis Res and Therapy 2010
CTD Estimated frequency of ILDSystemic sclerosis 45% (clinically significant)Rheumatoid arthritis 20 – 30% PM/DM 20 – 50%MCTD 20 – 60%Sjögren's syndrome Up to 25%SLE 2 to 8 %
Interstitial lung disease in scleroderma
• The majority of SSc patients have ILD
• F-NSIP is the most common pattern – UIP far less common– Rare to see the other patterns
• Clinically progressive in ~30%
• The leading cause of death
Solomon et al. Eur Resp Reviews 2013
ILD in poly-/dermatomyositis• ILD is the most common lung
manifestation of PM/DM
• Chief cause of mortality
• NSIP and NSIP/OP are the most common patterns– Can also see LIP, DAD, UIP
• Varied presentation
• Anti-synthetase syndrome
Miller et al. Rheum Dis Clinics NA 2015
-
11/5/2016
3
Interstitial lung disease in RA• ILD is the most common lung
manifestation of RA
• Varied presentation
• UIP is the most common pattern– Can also see NSIP, OP, LIP, DAD
• Accounts for 7% of all RA-associated deaths
• Risk of death is 3x higher than for RA without ILD
K Brown Proc Am Thor Soc 2007, Doyle CHEST 2013, Olson AJRCCM 2011
familial
CTD-ILD
medications
idiopathic
environmental occupational
smoking
infection?
??
?
?
?
?
?
the clinical landscape
Park et al. AJRCCM 2007;175:705-711
why assess for CTD?
A CTD-ILD diagnosis may impact:
• Treatment
• Prognosis
• Extra-thoracic disease– clinical context– surveillance for other features
CTD-ILD
IIP
Current approach to treatment
Idiopathic UIP(IPF)
CTD-ILD(ANY pattern) Idiopathic non-UIP
Clinical trialsLung transplantation Immunosuppression Immunosuppression
PirfenidoneNintedanib
-
11/5/2016
4
Other common – and potentially important –reasons to assess for CTD
Patient perspective:
• emotional
• sense of belonging
• frustrations with being labeled as “idiopathic”
Physician perspective:
• “if it’s CTD, I can do something about it”
• “the last thing I want to tell my patients is that it's idiopathic”
ILD in established CTD:
Determine whether ILD is CTD-associated
““““Idiopathic”””” ILD:
Identifyingoccult CTD
““““Idiopathic”””” ILD:
Is it really CTD?
the clinical landscape
55-year-old man former smoker, develops exertional dyspnea and cough…
• 10-year history of RF / CCP positive, erosive RA
• arthritis well controlled on MTX and an anti-TNF agent
• crackles at B/L bases
• chronic RA deformities without synovitis
• FVC 74%, FEV-1 73%, DLCO 64%
• ESR 15 Is this CTD-ILD?
ILD in established CTD: checklist1. Confirm the CTD
2. Consider alternative etiologies
3. Determine whether the ILD pattern “fits”
4. BAL to exclude infection
5. Biopsy the atypicalsConcluding ILD is “CTD-associated”
is a process of elimination
-
11/5/2016
5
DIAGNOSTIC EVALUATION OF ILD IN CTD
SYMPTOMS
PHYSICAL EXAM
RISK FACTORS
CTD PHENOTYPIC ASPECTS
PULMONARY PHYSIOLOGY
DIAGNOSTIC IMAGING
BRONCHOSCOPY
BIOPSY Symptoms• Dyspnea may be due to
any number of causes– MSK impact / extra-thoracic
disease– Sedentary patients /
deconditioning – Cardiac– Anemia (e.g., GAVE)– Depression
• Unreliable reporting• Unreliable assessment
• Assess impact of dyspnea on ADLs, other activities
• Pace / progression
• Cough more likely to be due to GERD
• Absence of dyspnea does not mean absence of ILD
Physical exam
• Audible bibasilar crackles strongly predictive of ILD
• Absence of crackles does not mean absence of ILD
• Skin informs about skin. Not the lungs.– Same can be said re: joints in RA and muscles in myositis
High risk of missing significant SSc-ILD when relying solely on PFTs
64/102 (63.0%) with significant ILD on HRCT
27/102 (26.0%) had an FVC
-
11/5/2016
6
High resolution CT imaging• Modality of choice for detecting
CTD-ILD
• Easy method to determine disease extent– i.e., disease severity
• Multi-compartment disease• Esophageal findings
• May suggest pulmonary vascular disease: PA diameter, pericardial abnormalities
Role of surgical lung biopsy?Clinical realities:
• May not impact treatment
– Immunosuppression may be needed – for ILD and the extra-thoracic disease – irrespective of ILD pattern
• Risks associated with the surgery
Park et al, AJRCCM 2007
Staging system – not histopathology – predicts prognosis in SSc-ILD
215 consecutive SSc patients evaluated at the Royal BromptonHospital between 1990 and 1999
Goh et al. AJRCCM 2008
-
11/5/2016
7
When do I recommend a surgical lung biopsy?
• pre-existing CTD and concerns for an alternative etiology
• “atypical” HRCT
• idiopathic ILD – and thinking it may be CTD
• ultimately, the decision is individualized 35 year old limited SSc and positive Scl-70
ILD in established CTD:
Determine whether ILD is CTD-associated
““““Idiopathic”””” ILD:
Identifyingoccult CTD
““““Idiopathic”””” ILD:
Is it really CTD?
the clinical landscape
identifying new CTD in those presenting with ILD is common
114 consecutive patients evaluated in an ILD referral center
34 (30%) with well-defined CTD
17 (15%) with well established CTD prior to ILD
17 (15%) diagnosed with new CTD
Mittoo S et al. Resp Med 2009. 103:1152
Identifying occult CTD: what’s helpful?• demographics
– 40 year old women don’t get IPF
• extrathoracic manifestations
• serologies
• HRCT findings
• histopathology
which ones?
-
11/5/2016
8
Quantifiable, specific extra-thoracic features suggesting CTD
• Sclerodactyly• Mechanic hands• Gottron’s papules• Digital edema• Raynaud’s
– capillary microscopy • inflammatory arthritis of
bilateral wrists or MCPs• KCS sicca?• Esophageal dilation /
hypomotility
tortuosity
dilatation dropout
Useful autoantibodies for CTD-ILD (?)Most common CTD association
High-titer ANA (>1:320) Many
RF (>60 IU/mL) Many / RA
Anti-centromere SSc
Nucleolar-ANA SSc
Anti-CCP RA
Anti-Scl-70 SSc
Anti-Ro (SS-A) Many
Anti-tRNA synthetase (Jo-1, PL-7, PL-12, others) PM / DM
Anti-PM-Scl SSc / PM overlap
Anti-La (SS-B) Sjögren's ’’’’s, SLE
Anti-dsDNA SLE
Anti-RNP MCTD, SLE / SSc
Anti-Smith SLE
Anti-MDA-5 CADM
HRCT clues for CTD-ILD
• multi-compartment involvement
• dilated esophagus
• pericardial thickening or effusion
• NSIP, LIP, NSIP/OP, OP, (UIP)
Fischer et al Resp Med 2009Hwang et al J Comput Assist Tomogr 33, 410-5
Histopathology features of CTD-ILD
• secondary histopathologic features:– dense perivascular
collagen– extensive pleuritis– lymphoid aggregates
with germinal center formation
– prominent plasmacytic infiltration
– inflammatory airways• follicular bronchiolitis
• “multi-compartment”involvement– parenchyma, airways,
vascular, pleura
• Primary patterns– NSIP, OP, LIP– UIP– DAD
Leslie et al Semin Respir Crit Care Med 2007;28(4):369
-
11/5/2016
9
Two “common” spectra worth highlighting…
• Subtle scleroderma spectrum
• Subtle myositis spectrum
systemic sclerosis (SSc)
limited cutaneous SScdiffuse cutaneous SSc
SSc sine sclerodermaDiffuse
“easier” to diagnose;present to rheumatologists
Limited / Sinemore subtlemay only come to attention due to lung disease
• Classic presentation:– Jo-1 positive– ILD – Myositis– Raynaud’s phenomenon– “mechanic hands”– Inflammatory arthritis– Often ANA negative
• Other tRNA synthetase antibodies have been identified but not routinely checked
anti-synthetase syndrome
““““mechanic hands ””””
screening for CTD-ILD with an ANA, ANA profile, RF, CCP, and Scl-70, misses the anti-synthetase syndrome
and many of these patients do NOT have myositis
-
11/5/2016
10
ILD in established CTD:
Determine whether ILD is CTD-associated
““““Idiopathic”””” ILD:
Identifyingoccult CTD
““““Idiopathic”””” ILD:
Is it really CTD?
the clinical landscape CTD-ILD?• 67 year-old woman
with exertional dyspnea
• long-standing Raynaud’s phenomenon
• ANA negative• Isolated Ro-52 positive• HRCT: possible UIP• VATS: UIP with lymphoid
aggregates
CTD-ILD?• 40 year-old woman
with nothing extra-thoracic
• ANA positive 1:320 speckled
• biopsy-proven NSIP • overlapping features:
• organizing pneumonia• lymphoid follicles with
germinal centers
CTD-ILD?• 60 year-old man
• Recent onset Raynaud’s phenomenon
• HRCT with fibrosing interstitial pneumonia
• ANA 1:640 speckled
-
11/5/2016
11
CTD-ILD?• 55 year old woman
• No arthritis or other CTD features
• HRCT = UIP
• High titer RF positive• High titer CCP positive
Statement of the problem• Many patients with IIP have subtle features suggestive of an
autoimmune etiology
• Current strategies for identifying and classifying these patients are controversial and inadequate
• Proposed terminology:– “UCTD”, “lung-dominant CTD”, and “auto-immune featured ILD”
• Each have their own set of proposed criteria • None have been validated
• Multi-centered prospective studies are needed to answer important questions about the natural history of this ILD subgroup
Existing criteria only partly overlap
Assayag D et al, Respir Med 2015
• 119 patients with chronic fibrosing interstitial pneumonia
• 4 different set of criteria for interstitial pneumonia with features of autoimmunity
Patients with interstitial pneumonia with features of autoimmune disease have improved survival compared to patients that do not
P=0.03 P=0.06
P=0.07 P=0.10
Assayag D et al, Respir Med 2015
These data support the efforts to standardize the definition
Autoimmune featuresAutoimmune features
Autoimmune featuresAutoimmune features
-
11/5/2016
12
“Interstitial Pneumonia with Autoimmune Features” (IPAF)
Courtesy of Prof V CottinFischer et al ERJ July 2015
Interstitial Pneumonia with Autoimmune Features (IPAF)1. Presence of an interstitial pneumonia (by HRCT or surgical lung biopsy) and,2. Exclusion of alternative etiologies and,3. Does not meet criteria of a defined CTD and, 4. At least one feature from at least two of these domains:
A
B
C
67 year-old woman• Raynaud’s phenomenon• High titer Ro-52 / SS-A• VATS: UIP with extensive
lymphoid aggregates
Clinical domain
Serologic domain
Morphologic domain
The IPAF “intersect”
CTD-ILD
Idiopathic Interstitial
Pneumonia(IPF, iNSIP)
IPAF
Park et al. AJRCCM 2007;175:705-711
Do those with “IPAF” behave like CTD-ILD or IIP?
IPAF
?
?
-
11/5/2016
13
Summary• ILD in pre-existing CTD:
– Exclude alternative etiologies– Biopsy the atypical HRCT / atypical scenario– CTD-ILD = diagnosis of exclusion
• ILD as the first manifestation of CTD:– Multidisciplinary evaluations are useful– Remember the scleroderma and myositis spectrum disorders– Consider demographics, serologies, clinical features, radiology, pathology
• Challenges of suggestive forms of CTD-ILD:– Consider “interstitial pneumonia with autoimmune features”– Needs to be studied